Padmanabh P. Bhatt, Senior Vice President of IP and Chief Scientific Officer of Supernus Pharmaceuticals, Inc., filed a Form 4 on August 14, 2026, disclosing transactions in common stock on August 12, 2026, related to the vesting of Performance Share Units.

Key Highlights

  • PSU vesting: 2,500 Performance Share Units vested on August 12, 2026, converting to 2,500 shares of common stock at $0 exercise price.
  • Shares withheld for taxes: 1,158 shares were withheld by the company to satisfy tax withholding requirements, at a price of $46.57 per share.
  • Beneficial ownership after transactions: Bhatt directly holds 18,637 shares of common stock following the reported transactions.
  • PSU award origin: The Performance Share Units were originally awarded on February 19, 2025, with individual performance objectives established on May 3, 2025.
  • ESPP shares included: The post-transaction total includes 251 shares acquired through the issuer's Employee Stock Purchase Plan.

Bhatt's PSU Vesting and Tax Withholding Transactions at Supernus Pharmaceuticals

According to the filing, Padmanabh P. Bhatt, identified as Sr. VP of IP and CSO at Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), reported two non-derivative transactions in common stock on August 12, 2026. The first was an acquisition of 2,500 shares coded "M," reflecting the conversion of Performance Share Units at a price of $0, which brought his directly held shares to 19,795 at that point. The filing notes that this total included 251 shares previously acquired through the company's Employee Stock Purchase Plan.

The second transaction, coded "F," recorded the disposal of 1,158 shares at $46.57 per share. The filing states this "represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units." Following this withholding, Bhatt's direct beneficial ownership stood at 18,637 shares of common stock.

In Table II, the filing discloses that the 2,500 Performance Share Units that vested were originally awarded on February 19, 2025. According to the filing, "a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025." The derivative security carried a conversion price of $0, and Bhatt's remaining balance of Performance Share Units following the transaction is reported as 0. The Form 4 was signed by Timothy C. Dec as attorney-in-fact on August 14, 2026.

What Was Disclosed

The filing reports the vesting of 2,500 Performance Share Units by Supernus Pharmaceuticals officer Padmanabh P. Bhatt on August 12, 2026, and the subsequent withholding of 1,158 shares at $46.57 each for tax purposes, leaving him with 18,637 directly owned shares.